Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
35 pending office actions • 26 art units • 35 examiners • 0 of 35 (0%) have an AI response strategy ready • 26 patents granted in the last 365 days
Emory University has 36 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 36 distinct examiners and 27 distinct art units, indicating that every pending matter has a distinct examiner assignment while technical work is distributed across a smaller set of art units. This pattern requires strong matter-level controls and coordinated review of recurring scientific themes.
KUO, JONATHAN T is the busiest examiner, with 1 pending matter. The supplied data shows no examiner concentration. Counsel should therefore avoid treating one examiner's approach as portfolio-wide and should tailor each response to its assigned art unit and prosecution record.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (14%) |
| §103 only | 6 (17%) |
| §102 only | 1 (3%) |
| §112 only | 3 (9%) |
| Double-patenting + other | 6 (17%) |
| Multi-statute (no §101) | 14 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KUO, JONATHAN T | 1 | 72.4% | +29.0% |
| NAH, JONGBONG | 1 | 76.0% | +17.5% |
| RICCI, CRAIG D | 1 | 53.7% | +52.6% |
| HUYNH, VAN D | 1 | 87.1% | +13.2% |
| RUSSELL, SYDNEY REYES | 1 | 51.4% | +56.8% |
| LUKJAN, SEBASTIAN X | 1 | 76.4% | +40.1% |
| STOCKTON, LAURA LYNNE | 1 | 75.3% | +33.7% |
| BANERJEE, KOYELI | 1 | 33.3% | +0.0% |
| GRABER, JAMES J | 1 | 46.5% | +57.6% |
| CHAO, ALLEN | 1 | 60.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18000865 | DIRECT IN VIVO REPROGRAMMING USING TRANSCRIPTION FACTOR ETV2 GENE FOR ENDOTHELIAL CELL AND VESSEL FORMATION | KIM, TAEYOON | 49d overdue |
| 17435594 | Botanical Extracts and Compounds from Castanea Plants and Methods of Use | ISMAIL, REHANA | 30d overdue |
| 18558026 | CELL POTENCY ASSAYS, PLATFORMS, AND METHODS OF USE | ARMATO JR, DENNIS IGNATIUS | 6d |
| 18564391 | SYSTEMS AND METHODS OF USING NANOMEMBRANE ELECTRONICS | SOLOMON, JOSHUA BRENDON | 48d |
| 18993727 | RECORDING AND RECOVERY OF SIGNALS DURING STIMULATION | KUO, JONATHAN T | — |
| 18853643 | Indolium Compounds for Treating Cancer | RICCI, CRAIG D | — |
| 18901408 | MEDICAL ANALYSIS USING SPATIOTEMPORAL ANALYSIS AND TRANSFORMER-BASED MODELS | HUYNH, VAN D | — |
| 18847528 | PNEUMATIC COMPRESSION VEST DEVICE, METHOD, AND SYSTEM FOR TRANSTHORACIC MANIPULATION FOR OXYGENATION | RUSSELL, SYDNEY REYES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18993727 | RECORDING AND RECOVERY OF SIGNALS DURING STIMULATION | KUO, JONATHAN T | — |
| 18961390 | Systems and Methods for Correcting Intravoxel and/or Voxel Inhomogeneity | NAH, JONGBONG | — |
| 18853643 | Indolium Compounds for Treating Cancer | RICCI, CRAIG D | — |
| 18901408 | MEDICAL ANALYSIS USING SPATIOTEMPORAL ANALYSIS AND TRANSFORMER-BASED MODELS | HUYNH, VAN D | — |
| 18847528 | PNEUMATIC COMPRESSION VEST DEVICE, METHOD, AND SYSTEM FOR TRANSTHORACIC MANIPULATION FOR OXYGENATION | RUSSELL, SYDNEY REYES | — |
| 18819710 | SYSTEM AND METHODS FOR AUTOMATED DEEP BRAIN STIMULATION PARAMETER SELECTION VIA META-ACTIVE LEARNING OF EVOKED POTENTIALS | LUKJAN, SEBASTIAN X | — |
| 18756360 | Nucleoside Prodrugs and Uses Related Thereto | STOCKTON, LAURA LYNNE | — |
| 18680912 | Methods of Producing Astrocytes or Promoting Astrocyte Development and Cell Culture Compositions Related Thereto | GRABER, JAMES J | — |
| Art Unit | Apps |
|---|---|
| 3792 | 3 |
| 1631 | 3 |
| 1693 | 3 |
| 1622 | 2 |
| 1691 | 2 |
| 1625 | 2 |
| 2674 | 1 |
| 1611 | 1 |
| 2665 | 1 |
| 3785 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18993727 | RECORDING AND RECOVERY OF SIGNALS DURING STIMULATION | KUO, JONATHAN T | 3792 | §102§103§112 | Non-Final OA | — | Pending | Jan 13, 2025 |
| 18961390 | Systems and Methods for Correcting Intravoxel and/or Voxel Inhomogeneity | NAH, JONGBONG | 2674 | §103 | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18853643 | Indolium Compounds for Treating Cancer | RICCI, CRAIG D | 1611 | §102§112 | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18901408 | MEDICAL ANALYSIS USING SPATIOTEMPORAL ANALYSIS AND TRANSFORMER-BASED MODELS | HUYNH, VAN D | 2665 | §102§103 | Non-Final OA | — | Pending | Sep 30, 2024 |
| 18847528 | PNEUMATIC COMPRESSION VEST DEVICE, METHOD, AND SYSTEM FOR TRANSTHORACIC MANIPULATION FOR OXYGENATION | RUSSELL, SYDNEY REYES | 3785 | §102§103§112 | Non-Final OA | — | Pending | Sep 16, 2024 |
| 18819710 | SYSTEM AND METHODS FOR AUTOMATED DEEP BRAIN STIMULATION PARAMETER SELECTION VIA META-ACTIVE LEARNING OF EVOKED POTENTIALS | LUKJAN, SEBASTIAN X | 3792 | §101§102§103§112 | Final Rejection | — | Pending | Aug 29, 2024 |
| 18756360 | Nucleoside Prodrugs and Uses Related Thereto | STOCKTON, LAURA LYNNE | 1626 | §112DP | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18742659 | RNA-Dependent RNA Polymerase Inhibitory Compounds, Uses in Managing Viral Infections, and Pharmaceutical Compositions | BANERJEE, KOYELI | 1658 | §103§112 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18680912 | Methods of Producing Astrocytes or Promoting Astrocyte Development and Cell Culture Compositions Related Thereto | GRABER, JAMES J | 1631 | §102§112 | Non-Final OA | — | Pending | May 31, 2024 |
| 18709395 | Prodrugs of Neurosteroid Analogs and Uses Thereof | CHAO, ALLEN | 1622 | §112DP | Non-Final OA | — | Pending | May 10, 2024 |
| 18709256 | Prodrugs of Neurosteroid Analogs and Uses Thereof | JAVANMARD, SAHAR | 1622 | §112 | Non-Final OA | — | Pending | May 10, 2024 |
| 18702922 | TREATMENT OF VIRUSES WITH ANTIVIRAL NUCLEOSIDES | CHO, DAVID H | 1693 | §103§112DP | Non-Final OA | — | Pending | Apr 19, 2024 |
| 18698693 | 3D AUXETIC STRUCTURES AND FABRICATION METHODS THEREOF | STEWART, ALVIN J | 3799 | §102 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18612453 | SYSTEMS AND METHODS FOR DRIVING NEURAL ACTIVITY TO CONTROL BRAIN SIGNALING AND GENE EXPRESSION | DORNA, CARRIE R | 3791 | §112DP | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18292483 | Methods of Improving Therapeutic Efficacy of Mesenchymal Stromal Cells for Treatment of Osteoarthritis | KASAYAN, KATRIEL BARCELLANO | 1634 | §101§103§112 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18291630 | PHOSPHATE PRODRUGS OF CANNABINOIDS | RAHMANI, NILOOFAR | 1691 | §102§112 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18579142 | T Cell Receptors (TCR) to Human Papillomavirus Proteins, Compositions, and Uses Thereof | GODDARD, LAURA B | 1642 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18572536 | 3-Iodopropyl-1,2,3-Triazol-1-yl, 3-Bromopropyl-1,2,3-Triazol-1-yl, and Derivatives for Uses in Labeling | LEWOCZKO, EVAN MICHAEL | 1612 | §103DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18542096 | SYSTEMS AND METHODS TO MEASURE OCCLUSION OF BLOOD CELLS IN MICROFLUIDIC CHANNELS | ORANGE, DAVID BENJAMIN | 2663 | §102§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18527046 | Catheter Retention Device | STIMPERT, PHILIP EARL | 3783 | §102§103§112 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18564391 | SYSTEMS AND METHODS OF USING NANOMEMBRANE ELECTRONICS | SOLOMON, JOSHUA BRENDON | 3792 | §101§103 | Non-Final OA | 48d | Pending | Nov 27, 2023 |
| 18561673 | JAK Inhibitors for Managing Conditions in Patients with Down's Syndrome or Other Trisomy | LANDSMAN, ROBERT S | 1647 | §112 | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18510060 | Methods of Treating Cancer and Infectious Diseases Using Cell Based Therapies | SINGH, ANOOP KUMAR | 1632 | §103§112DP | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18558874 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | GALSTER, SAMUEL LEONARD | 1693 | §103 | Final Rejection | — | Pending | Nov 03, 2023 |
| 18558026 | CELL POTENCY ASSAYS, PLATFORMS, AND METHODS OF USE | ARMATO JR, DENNIS IGNATIUS | 1651 | §102§112 | Final Rejection | 6d | Pending | Oct 30, 2023 |
| 18285778 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | LEWIS, PATRICK T | 1691 | §103 | Non-Final OA | 2d overdue | Pending | Oct 05, 2023 |
| 18285789 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | LAU, JONATHAN S | 1693 | §103§112 | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18274682 | Rotatable Hip Prosthesis | DUDDEN, TERESA MARIE | 3774 | §112 | Final Rejection | — | Pending | Jul 27, 2023 |
| 18176021 | CIRCULAR RNAS AND THEIR USE IN IMMUNOMODULATION | LEONARD, ARTHUR S | 1631 | §103 | Final Rejection | — | Pending | Feb 28, 2023 |
| 18111350 | RESPONSE-GUIDED HCV THERAPY | CHANDRAKUMAR, NIZAL S | 1625 | §103§112 | Non-Final OA | — | Pending | Feb 17, 2023 |
| 18000865 | DIRECT IN VIVO REPROGRAMMING USING TRANSCRIPTION FACTOR ETV2 GENE FOR ENDOTHELIAL CELL AND VESSEL FORMATION | KIM, TAEYOON | 1631 | §102§103 | Non-Final OA | 49d overdue | Pending | Dec 06, 2022 |
| 17925179 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING A SARS-COV-2 INFECTION | SALVOZA, M FRANCO G | 1672 | §103§112 | Non-Final OA | — | Pending | Nov 14, 2022 |
| 17908766 | Radionuclide Tracers of 1-Amino-3,4-Difluorocyclopentane-1-Carboxylic Acid, Derivatives, and Uses Thereof | WESTERBERG, NISSA M | 1618 | §103 | Non-Final OA | 67d overdue | Pending | Sep 01, 2022 |
| 17842433 | CSF-BASED PROGNOSTIC BIOMARKERS IN ALZHEIMER'S DISEASE AND METHODS OF USE THEREOF | FRITCHMAN, REBECCA M | 1758 | §103 | Final Rejection | — | Pending | Jun 16, 2022 |
| 17435594 | Botanical Extracts and Compounds from Castanea Plants and Methods of Use | ISMAIL, REHANA | 1625 | §101§102§112 | Final Rejection | 30d overdue | Pending | Sep 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEmory University has 35 pending office actions as of October 2026, spread across 26 art units and 35 examiners.
Jonathan T Kuo has the most, with 1 of Emory University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
